The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice

European Journal of Health Economics

Volumn 14, Issue 6, 2013, Pages 863-873

  Lekander, Ingrid ^a,b,f   Borgström, Fredrik ^a,b   Lysholm, Jörgen ^c   Van Vollenhoven, Ronald F ^a   Lindblad, Staffan ^a   Geborek, Pierre ^d   Kobelt, Gisela ^e  

^a KAROLINSKA INSTITUTE   (Sweden)

^b i3 Innovus   (Sweden)

^c FALUN HOSPITAL   (Sweden)

^d LUND UNIVERSITY   (Sweden)

^e Speracedes   (France)

^f NONE   (Sweden)

Author keywords

Anti TNF; Clinical practice; Cost effectiveness analysis; Disease progression; Etanercept; Registry data; Retrospective; Rheumatoid arthritis; Sweden

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DAS28; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH CARE COST; HUMAN; MONOTHERAPY; MORTALITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS;

AGE FACTORS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOGLOBULIN G; QUALITY-ADJUSTED LIFE YEARS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; SEX FACTORS; SWEDEN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84888432068     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-012-0431-6     Document Type: Article

References (35)

1. Hurst, N.P.; Kind, P.; Ruta, D.; Hunter, M.; Stubbings, A.: Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br. J. Rheumatol. 36(5), 551-559 (1997)
2. Kobelt, G.; Lindgren, P.; Lindroth, Y.; Jacobson, L.; Eberhardt, K.: Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. Rheumatology (Oxford) 44(9), 1169-1175 (2005)
3. Kobelt, G.; Woronoff, A.S.; Richard, B.; Peeters, P.; Sany, J.: Disease status, costs and quality of life of patients with rheumatoid arthritis in France: the ECO-PR Study. Jt. Bone Spine 75(4), 408-415 (2008)
4. Allaire, S.H.; Prashker, M.J.; Meenan, R.F.: The costs of rheumatoid arthritis. Pharmacoeconomics 6(6), 513-522 (1994)
5. Kobelt, G.; Eberhardt, K.; Jonsson, L.; Jonsson, B.: Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthr. Rheum. 42(2), 347-356 (1999)
6. Chen, Y.F.; Jobanputra, P.; Barton, P.; Jowett, S.; Bryan, S.; Clark, W.; et al.: A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol. Assess. 10(42), 1-248 (2006)
7. Doan, Q.V.; Chiou, C.F.; Dubois, R.W.: Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. J. Manag. Care Pharm. 12(7), 555-569 (2006)
8. Kobelt, G.; Eberhardt, K.; Geborek, P.: TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann. Rheum. Dis. 63(1), 4-10 (2004)
9. Lekander, I.; Borgstrom, F.; Svarvar, P.; Ljung, T.; Carli, C.; van Vollenhoven, R.F.: Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden. Int. J. Technol. Assess. Health Care 26(1), 54-61 (2010)
10. Kobelt, G.; Lindgren, P.; Singh, A.; Klareskog, L.: Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann. Rheum. Dis. 64(8), 1174-1179 (2005)
11. TLV: Läkemedelsförmånsnämndens allmänna råd om ekonomiska utvärderingar http://www.tlv.se/Upload/Lagar-och- foreskrifter/LAG-lfnar-2003-2.pdf, downloaded on 7 July 2012
12. Scott, D.L.; Pugner, K.; Kaarela, K.; Doyle, D.V.; Woolf, A.; Holmes, J.; et al.: The links between joint damage and disability in rheumatoid arthritis. Rheumatology (Oxford) 39(2), 122-132 (2000)
13. Brennan, A.; Bansback, N.; Reynolds, A.; Conway, P.: Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology (Oxford) 43(1), 62-72 (2004)
14. Wolfe, F.; Michaud, K.: The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study. Arthritis. Res. Ther. 12(2), R35 (2010)
15. Ariza-Ariza, R.: Dose escalation of the anti-TNF alpha agents in patients eith rheumatois arthritis. A systematic review. Rheumatology (Oxford) 46(3), 529-532 (2007)
16. Berger, A.; Edelsberg, J.; Li, T.T.; Maclean, J.R.; Oster, G.: Dose intensification with infliximab in patients with rheumatoid arthritis. Ann. Pharmacother. 39(12), 2021-2025 (2005)
17. Fitzcharles, M.A.; Clayton, D.; Menard, H.A.: The use of infliximab in academic rheumatology practice: an audit of early clinical experience. J. Rheumatol. 29(12), 2525-2530 (2002)
18. Haraoui, B.; Cameron, L.; Ouellet, M.; White, B.: Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J. Rheumatol. 33(1), 31-36 (2006)
19. Stern, R.; Wolfe, F.: Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis. J. Rheumatol. 31(8), 1538-1545 (2004)
20. Wolbink, G.J.; Vis, M.; Lems, W.; Voskuyl, A.E.; de Groot, E.; Nurmohamed, M.T.; et al.: Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 54(3), 711-715 (2006)
21. van Vollenhoven, R.; Klareskog, L.: Infliximab dosage and infusion frequency in clinical practice: experiences in the Stockholm biologics registry STURE. Scand. J. Rheumatol. 36(6), 418-423 (2007)
22. Hetland, M.L.; Christensen, I.J.; Tarp, U.; Dreyer, L.; Hansen, A.; Hansen, I.T.; et al.: Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 62(1), 22-32 (2010)
23. SRR: Svenska Reumatologis Kvalitetsregister - Årsrapport 2008-09. http://www.swerrese/documents/AllaAR09pdf2009; downloaded 25 February 2010
24. Leden I: Rapport från vårdprocess:Reumatologi dyr läkemedelsbehandling. 2003
25. van Vollenhoven, R.; Cullinane Carli, C.; Augustsson, J.; Bratt, J.; Klareskog, L.:. Patients treated with TNFA antagonists increase their partricipations in the work-force - potential for significant long-term indirect cost of gains. EULAR 2006; abstract SAT 0200 2006
26. Askling, J.; Fored, C.M.; Brandt, L.; Baecklund, E.; Bertilsson, L.; Coster, L.; et al.: Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum. 52(7), 1986-1992 (2005)
27. Askling, J.; Fored, C.M.; Brandt, L.; Baecklund, E.; Bertilsson, L.; Feltelius, N.; et al.: Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann. Rheum. Dis. 66(10), 1339-1344 (2007)
28. Geborek, P.; Crnkic, M.; Petersson, I.F.; Saxne, T.: Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann. Rheum. Dis. 61(9), 793-798 (2002)
29. Askling, J.: Risk for tuberculosis following treatment of rheumatoid arthritis with anti-TNF therapy - the Swedish experience 1998-2008. Ann. Rheum. Dis. 68(Suppl 3), 422 (2009)
30. LFN:. Kostnadseffektiva läkemedel - LFN http://www.lfn.se/upload/ Bakgrundsmaterial/kostnadseffektiva-lakemedel.PDF, downloaded on 25 September 2008
31. Soderlin, M.K.; Geborek, P.: Changing pattern in the prescription of biological treatment in rheumatoid arthritis. A 7-year follow-up of 1839 patients in southern Sweden. Ann. Rheum. Dis. 67(1), 37-42 (2008)
32. Smolen, J.S.; Landewé, R.; Breedveld, F.C.; Dougados, M.; Emery, P.; Gaujoux-Viala, C.; et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann. Rheum. Dis. 2010(69), 964-975 (2010)
33. Brennan, A.; Bansback, N.; Nixon, R.; Madan, J.; Harrison, M.; Watson, K.; et al.: Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology (Oxford) 46(8), 1345-1354 (2007)
34. Benucci, M.; Li, G.F.; Sabadini, L.; Saviola, G.; Baiardi, P.; Manfredi, M.: The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients. Int. J. Immunopathol. Pharmacol. 22(4), 1147-1152 (2009)
35. Virkki, L.M.; Konttinen, Y.T.; Peltomaa, R.; Suontama, K.; Saario, R.; Immonen, K.; et al.: Cost-effectiveness of infliximab in the treatment of rheumatoid arthritis in clinical practice. Clin. Exp. Rheumatol. 26(6), 1059-1066 (2008)